Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety
Annals of Pharmacotherapy · 10.08.2026
DOI: 10.1177/10600280261470829 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 10.08.2026. Verfasst von Emily Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA. Die Arbeit nennt 72 Literaturangaben.
Abstract (Originalsprache)
Objective
This article reviews the published data encompassing the development, pharmacology, efficacy, and safety of obecabtagene autoleucel, summarizing data from pivotal clinical studies and clinical relevance in the treatment of relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL). Data Sources: A literature review was conducted in PubMed and Clinicaltrials.gov from inception through May 2026, using terms “AUCATZYL®,” “obecabtagene autoleucel,” “obe-cel,” “AUTO1,” and “CAR-T cell therapy.” Study Selection and Data Extraction: Clinical data and studies were limited to those published in the English language which discussed the safety and efficacy of obecabtagene autoleucel. Data Synthesis: Obecabtagene autoleucel (obe-cel) is an autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy using a novel CAT19 single-chain variable fragment designed with an intermediate affinity and fast binding off-rate mechanism. In the pivotal FELIX study, an overall remission rate of 77% was achieved in the primary adult cohort (IIa), with a median event-free survival rate of 11.9 months across all cohorts. Safety data indicate a manageable toxicity profile, and economic models suggest significant cost savings regarding adverse event management. Relevance to Patient Care and Clinical Practice in Comparison to Existing Agents: Obe-cel provides a new treatment option for adults with R/R B-ALL, a population that historically faces poor prognosis and high recurrence rates.
Conclusion
While logistical complexities and high acquisition costs remain an access barrier to CAR-T cell therapies, obe-cel’s molecular design and safety profile represent a significant advancement in the care of patients with R/R B-ALL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA.
ORCID-Profile: Kelli Corona, Lauren Carpenter, Jessica Huston
Zitieren
APA
Hu, E., Johnson, S., Abinsay, T., Confiado, M. A., Cobb, G., Corona, K., Carpenter, L., & Huston, J. (2026). Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261470829
Vancouver
Hu E, Johnson S, Abinsay T, Confiado MA, Cobb G, Corona K, et al. Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261470829
BibTeX
@article{Hu2026,
author = {Hu, Emily and Johnson, Sarah and Abinsay, Timber and Confiado, Michael Angelo and Cobb, Grace and Corona, Kelli and Carpenter, Lauren and Huston, Jessica},
title = {Obecabtagene Autoleucel in Relapsed/Refractory B-ALL: A Critical Review of Clinical Efficacy and Safety},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261470829}
}
EUVIMED